Allogene Therapeutics, Inc. Common Stock
ALLO US0197701065
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -42% | -59% | -44% | -41% | -2% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Messemer Deborah M. |
1.42 USD |
36,885 Sold |
52,377 USD |
10/06/2025 | 10/06/2025 |
| Messemer Deborah M. |
1.42 USD |
36,885 Sold |
52,377 USD |
10/06/2025 | 10/06/2025 |
| Yoshiyama Annie VP |
1.41 USD |
9,601 Sold |
13,537 USD |
21/04/2025 | 21/04/2025 |
| Chang David D CEO |
1.96 USD |
46,668 Sold |
91,469 USD |
14/03/2025 | 14/03/2025 |
| Beneski Benjamin Machinas VP |
1.98 USD |
5,488 Sold |
10,839 USD |
14/03/2025 | 14/03/2025 |
| Messemer Deborah M. |
2.43 USD |
13,313 Sold |
32,351 USD |
18/02/2025 | 18/02/2025 |
| Moore Timothy L. CTO |
1.71 USD |
14,746 Sold |
25,216 USD |
03/02/2025 | 03/02/2025 |
| Chang David D CEO |
1.68 USD |
46,003 Sold |
77,285 USD |
03/02/2025 | 03/02/2025 |
| Roberts Zachary EX VP |
1.70 USD |
18,832 Sold |
32,014 USD |
03/02/2025 | 03/02/2025 |
| Douglas Earl Martin SR VP |
1.71 USD |
6,404 Sold |
10,951 USD |
03/02/2025 | 03/02/2025 |